Archived Investigations

Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS)

March 31, 2026

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Apellis will receive $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Recent Investigations

Recent Victories

Chancery Sustains KSF’s Claims in Trecora Merger Litigation

Vice Chancellor Nathan A. Cook denied the defendants’ motion to dismiss KSF's class action complaint in its entirety. KSF's complaint, filed in the Delaware Court of Chancery on behalf of former stockholders of Trecora Resources Inc., alleges that Trecora’s directors breached their duty of loyalty in connection with the sale of Trecora.